Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-alpha therapy

FİDAN S., ÇAPKIN E., Arica D., DURAK S., Okatan I. E.

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, vol.24, no.2, pp.254-259, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 2
  • Publication Date: 2021
  • Doi Number: 10.1111/1756-185x.14034
  • Journal Name: INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, MEDLINE
  • Page Numbers: pp.254-259
  • Keywords: antirheumatic therapy, anti&#8208, tumor necrosis factor therapy, hepatitis B, hepatitis B virus reactivation, hepatitis B virus screening, VIRUS HBV REACTIVATION, OCCULT CARRIERS, PREVENTION, GUIDELINES, SAFETY
  • Karadeniz Technical University Affiliated: Yes

Abstract

Objective The purpose of this study was to determine hepatitis B virus (HBV) screening rates in patients receiving anti-tumor necrosis factor (TNF)-alpha therapy and the frequency of HBV reactivation in patients with resolved hepatitis B virus infection (hepatitis B surface antigen [HBsAg] negative, hepatitis B core antibody [Anti-HBc] positive).